Chronic Cough - Pipeline Review, H2 2015
Summary
Global Markets Directs, Chronic cough - Pipeline Review, H2 2015, provides an overview of the Chronic coughs therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic cough and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic cough
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic cough
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Cough Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Cough - Overview 7
Chronic Cough - Therapeutics under Development by Companies 8
Chronic Cough - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Chronic Cough - Products under Development by Companies 11
Chronic Cough - Companies Involved in Therapeutics Development 12
Afferent Pharmaceuticals, Inc. 12
Ario Pharma Ltd 13
AstraZeneca Plc 14
Conrig Pharma ApS 15
Glenmark Pharmaceuticals Ltd. 16
Patara Pharma, Inc. 17
Chronic Cough - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
AF-219 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
cromolyn sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GRC-17536 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
lesogaberan - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ST-015 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
XEND-0501 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Chronic Cough - Recent Pipeline Updates 34
Chronic Cough - Dormant Projects 37
Chronic Cough - Discontinued Products 38
Chronic Cough - Product Development Milestones 39
Featured News & Press Releases 39
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 39
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List Of Tables
Number of Products under Development for Chronic Cough, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Clinical Stage Development, H2 2015 9
Comparative Analysis by Early Stage Development, H2 2015 10
Products under Development by Companies, H2 2015 11
Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 12
Chronic Cough - Pipeline by Ario Pharma Ltd, H2 2015 13
Chronic Cough - Pipeline by AstraZeneca Plc, H2 2015 14
Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2015 15
Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 16
Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2015 17
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 25
Chronic Cough Therapeutics - Recent Pipeline Updates, H2 2015 34
Chronic Cough - Dormant Projects, H2 2015 37
Chronic Cough - Discontinued Products, H2 2015 38
List Of Figures
Number of Products under Development for Chronic Cough, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Top 10 Targets, H2 2015 19
Number of Products by Stage and Top 10 Targets, H2 2015 19
Number of Products by Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Top 10 Routes of Administration, H2 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23
